GlassScriptPhysician profile
Lawrence P Wang
NPI 1922004704
$2,433.16
in general payments reported to CMS, 2019-2025
22 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $121 · 2021: $410 · 2022: $282 · 2023: $269 · 2024: $719 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $410.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $410.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $365.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $304.58 | 2019-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.20 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $186.00 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $124.98 | 2022 | |
| Lucid Diagnostics INC. | $115.13 | 2023 | |
| Pfizer INC. | $82.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $64.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $62.55 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $62.13 | 2020-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $57.64 | 2022-2023 | |
| Novo Nordisk INC | $55.35 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $46.25 | 2021-2025 | |
| Abbvie INC. | $45.98 | 2022-2023 | Vraylar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $45.50 | 2024 | (Ck7) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $36.53 | 2023 | |
| Exact Sciences Corporation | $33.92 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $18.93 | 2025 | Dupixent |
| Sanofi Pasteur INC. | $18.75 | 2023 | |
| Dexcom, INC. | $18.00 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.